@Tooheys8
Happy to be corrected, I suspect it is basically because it provides 'immediate access' to a much larger patient 'data-set' to move the 'breadth' of the testing/assessments forward far more quickly than waiting (and paying) for access to 'fresh' new-samples as they become available...
Reading between the lines, it seems exosomes have a 'shelf-life' as such, so will basically required UQ & IIQ to 'revert' to basically acquiring access to 'fresh samples' on an ongoing basis to move the test forward (get 'statistical runs' on the board with a significant sample size), collate and then, present to industry, hence the H2FY24 delay-statement...
ML
- Forums
- ASX - By Stock
- IIQ
- Ann: EXO-OC PROGRAM COMPLETES SERUM EQUIVALENCE STUDY
Ann: EXO-OC PROGRAM COMPLETES SERUM EQUIVALENCE STUDY, page-13
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IIQ (ASX) to my watchlist
|
|||||
Last
56.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $62.30M |
Open | High | Low | Value | Volume |
56.0¢ | 56.5¢ | 56.0¢ | $4.443K | 7.893K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 15446 | 56.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
58.5¢ | 380 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 15446 | 0.560 |
4 | 19206 | 0.555 |
5 | 37050 | 0.550 |
1 | 10000 | 0.545 |
1 | 5550 | 0.540 |
Price($) | Vol. | No. |
---|---|---|
0.585 | 380 | 1 |
0.590 | 9849 | 1 |
0.600 | 15002 | 2 |
0.620 | 11837 | 1 |
0.640 | 16800 | 1 |
Last trade - 15.42pm 23/08/2024 (20 minute delay) ? |
Featured News
IIQ (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online